Company intelligence / Profile preview

Fiit

Ownership: Private
Development stage: Other

Overview

Prior to bankruptcy in February 2019, FIT Biotech advanced its GTU-based DNA vaccine "FIT‑06" into clinical development for HIV. The company also had preclinical programs targeting cancer and tuberculosis. No late-stage or commercial results were reported before operations ceased.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccineGene therapyGene transport technology (GTU®)Antibody gene delivery technologies
Industry: Biotech

Beyond the preview

Go deeper on Fiit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fiit.

Explore the full profile